Johnson & Johnson said Thursday it will pay $850 million in cash for Proteologix, a relatively unknown private biotech working on treatments for immune-mediated diseases, including the crowded field of atopic dermatitis.
The deal is relatively small compared to J&J’s recent M&A activity, and it’s quite…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
